5-氯-2-甲基-3-硝基吡啶 | 1211533-93-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 5-氯-2-甲基-3-硝基吡啶
• 中文别名: 2-甲基-3-硝基-5-氯吡啶
• 英文名称: 2-methyl-3-nitro-5-chloropyridine
• 英文别名: 5-chloro-2-methyl-3-nitropyridine
• CAS: 1211533-93-5
• 化学式: C₆H₅ClN₂O₂
• 分子量: 172.571
• InChiKey: YEJGWUTXWBGOPG-UHFFFAOYSA-N

物化性质

• 沸点：
  230℃
• 密度：
  1.406
• 闪点：
  93℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  58.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Chloro-2-methyl-3-nitropyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Chloro-2-methyl-3-nitropyridine
CAS number: 1211533-93-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H5ClN2O2
Molecular weight: 172.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氯-2-甲基-3-硝基吡啶 在 palladium on activated charcoal 、 氢气 、 溴 、 sodium 、 sodium nitrite 作用下， 以 甲醇 、 水 、 甲苯 为溶剂， 生成 3-溴-2,5-二甲基吡啶
  参考文献：
  名称：

  一种2,5-二甲基-3-溴吡啶的合成方法

  摘要：

  本发明涉及有机化学领域，特别是一种2,5‑二甲基‑3‑溴吡啶的合成方法，包括以下几个步骤：1、丙二酸二乙酯和碱金属反应生成盐，再滴加2甲基‑3‑硝基‑5氯吡啶的甲苯溶液进行缩合反应，之后在酸性条件下脱羧得2,5‑二甲基‑3‑硝基吡啶；2、2,5‑二甲基‑3‑硝基吡啶在Pd/C催化下，甲醇作溶剂，加氢还原，抽滤，滤液浓缩，得2,5‑二甲基‑3‑氨基吡啶；3、2,5‑二甲基‑3‑氨基吡啶先与酸生成盐，冷却至‑9℃‑4℃，滴加液溴，滴完滴加亚硝酸钠水溶液，滴加完毕调节溶液pH为碱性，再进行萃取、干燥、浓缩，得2,5‑二甲基‑3‑溴吡啶。本发明方法的有益效果是：反应条件温和，收率高，且原料易得，成本较低，工艺路线短，具有工业化前景。

  公开号：

  CN107089939A
• 作为产物：
  描述：

  diethyl (5-chloro-3-nitropyridin-2-yl )propanedioate 在 盐酸 作用下， 以 水 为溶剂， 反应 20.0h， 以86%的产率得到5-氯-2-甲基-3-硝基吡啶
  参考文献：
  名称：

  EP3805212

  摘要：

  公开号：

文献信息

• [EN] SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY<br/>[FR] DÉRIVÉS D'OXINDOLE SPIRO-SUBSTITUÉS AYANT UNE ACTIVITÉ SUR AMPK
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014202580A1

  公开（公告）日：2014-12-24

  The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及具有有价值的药理特性的式(I)化合物，特别是AMPK激活剂，因此在治疗某些可以通过激活该受体预防或治疗的疾病方面具有用处。这些化合物适用于治疗和预防可以受该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
• [EN] IMIDAZOPYRROLIDINONE COMPOUNDS<br/>[FR] COMPOSÉS IMIDAZOPYRROLIDINONE
  申请人：NOVARTIS AG

  公开号：WO2013111105A1

  公开（公告）日：2013-08-01

  The invention relates to compounds of formula (I): (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.

  这项发明涉及式(I)的化合物：(I)如本文所述，包括这种化合物的药物制剂，以及在治疗由MDM2和/或MDM4活性介导的疾病或疾病中使用这种化合物的用途和方法，以及包含这种化合物的组合物。
• [EN] NEW 6-MEMBERED HETEROAROMATIC SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE CYANOINDOLINE À SUBSTITUTION HÉTÉROAROMATIQUE À 6 CHAÎNONS UTILISÉS COMME INHIBITEURS DE NIK
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2017125534A1

  公开（公告）日：2017-07-27

  The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

  本发明涉及公式（I）的药物制剂，用于治疗和/或预防哺乳动物，特别是用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病的NF-KB诱导激酶（NIK - 也称为MAP3K14）抑制剂。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物或药物组合物预防或治疗癌症、炎症性疾病、包括肥胖和糖尿病在内的代谢性疾病以及自身免疫性疾病的用途。
• [EN] NOVEL COMPOUNDS AS WIP1 INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS EN TANT QU'INHIBITEURS DE WIP1
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2012149102A1

  公开（公告）日：2012-11-01

  This invention relates to the use of acylated alanine derivatives for the modulation, notably the inhibition of the activity of WIP1. Suitably, the present invention relates to the use of acylated alanine derivatives in the treatment of cancer.

  本发明涉及酰化丙氨酸衍生物用于调节WIP1活性，特别是抑制其活性。适当地，本发明涉及酰化丙氨酸衍生物在癌症治疗中的应用。
• PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS
  申请人：Janssen Biotech, Inc.

  公开号：US20180170909A1

  公开（公告）日：2018-06-21

  Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 5 , G 1 , and G 2 are defined herein.

  揭示了一种通过调节MALT1来治疗受影响的疾病、综合症、症状和疾病的化合物、组合物和方法。这些化合物由以下式（I）表示：其中R1、R2、R3、R4、R5、R6、R5、G1和G2在此处定义。